Mesoblast Limited announced that the Phase III trial of its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in patients...
Mesoblast announced results from the Phase III randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy Revascor (rexlemestrocel-L) in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments.